Look, the 59 people are very ill, God bless them, and the platinum drugs cause peripheral neuropathy by themselves. 901 works and it works at a substantially lower dose than 90mg per sq.ltr blood. These guys are very smart. If they can get a therapeutic dose in a tough setting, they will figure it out. No one in the analyst world expects 901 to succeed, 901 failure is already priced in at 17.50. If the analysts were really top notch people, they would be on the other side of the podium... This company is just at the beginning of a growth curve. If you can buy it and bank it on a crazy dip, you're smart to do so.
John, couldn't agree more! This is just a reason for a market maker to move the stock and make money on options. The value hasn't changed one bit on this 901 update. Here's what Credit Suisse had in their most recent report - "Interim results from the NORTH trial. IMGN has a Stage I hurdle in the NORTH trial
that it expects to report on in H2:13. If IMGN901 clears that hurdle, investors will likely
begin to assign increased option value to this program in small cell lung cancer, which
currently is viewed as a low probability trial."